N
NEWAMSTERDAM PHARMA COMPANY N.V. ORDINARY SHARES
NASDAQ: NAMS (NewAmsterdam Pharma Company N.V)
Last update: 4 hours ago36.76
-0.29 (-0.78%)
| Previous Close | 37.05 |
| Open | 36.47 |
| Volume | 879,249 |
| Avg. Volume (3M) | 1,050,685 |
| Market Cap | 4,168,245,504 |
| Price / Sales | 51.43 |
| Price / Book | 4.44 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Operating Margin (TTM) | -2,314.47% |
| Diluted EPS (TTM) | -1.84 |
| Quarterly Revenue Growth (YOY) | 112.60% |
| Total Debt/Equity (MRQ) | 0.05% |
| Current Ratio (MRQ) | 19.98 |
| Operating Cash Flow (TTM) | -140.43 M |
| Levered Free Cash Flow (TTM) | -99.00 M |
| Return on Assets (TTM) | -18.15% |
| Return on Equity (TTM) | -31.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | NewAmsterdam Pharma Company N.V | Bullish | Bullish |
AIStockmoo Score
1.4
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -3.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.38 |
|
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 111.32% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Jun 2025 | 16,607,074 |
| Bain Capital Life Sciences Investors, Llc | 30 Jun 2025 | 10,719,110 |
| Fcpm Iii Services B.V. | 30 Jun 2025 | 10,632,113 |
| Ra Capital Management, L.P. | 30 Jun 2025 | 10,138,938 |
| Capital World Investors | 30 Jun 2025 | 8,387,725 |
| Viking Global Investors Lp | 30 Jun 2025 | 6,978,534 |
| Deerfield Management Company, L.P. | 30 Jun 2025 | 5,115,953 |
| Adage Capital Partners Gp, L.L.C. | 30 Jun 2025 | 3,013,009 |
| Medicxi Ventures Management (Jersey) Ltd | 30 Sep 2025 | 2,869,565 |
| Polar Capital Holdings Plc | 30 Jun 2025 | 2,517,779 |
| Cormorant Asset Management, Lp | 30 Jun 2025 | 2,175,000 |
| Capital International Investors | 30 Jun 2025 | 2,062,535 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (HC Wainwright & Co., 41.46%) | Buy |
| Median | 46.00 (25.14%) | |
| Low | 44.00 (RBC Capital, 19.70%) | Buy |
| Average | 47.40 (28.95%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 34.79 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| RBC Capital | 06 Nov 2025 | 44.00 (19.70%) | Buy | 37.05 |
| Needham | 05 Nov 2025 | 46.00 (25.14%) | Buy | 38.13 |
| HC Wainwright & Co. | 20 Oct 2025 | 52.00 (41.46%) | Buy | 37.66 |
| Citigroup | 17 Oct 2025 | 50.00 (36.02%) | Buy | 36.40 |
| Wells Fargo | 25 Aug 2025 | 45.00 (22.42%) | Buy | 24.70 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |